BST2 Antikörper (PE)
Kurzübersicht für BST2 Antikörper (PE) (ABIN2663359)
Target
Alle BST2 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Aufreinigung
- The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.
-
Isotyp
- IgG2b kappa
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Konzentration
- 0.2 mg/mL
-
Buffer
- Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handhabung
- Protect from prolonged exposure to light. Do not freeze.
-
Lagerung
- 4 °C
-
Informationen zur Lagerung
- The antibody solution should be stored undiluted between 2°C and 8°C.
-
-
- BST2 (Bone Marrow Stromal Cell Antigen 2 (BST2))
-
Andere Bezeichnung
- CD317
-
Hintergrund
- CD317, known as BST2, tetherin, HM1.2 antigen, bone marrow stromal antigen 2, or PDCA-1, is type II transmembrane glycoprotein with a molecular mass of 29-33 kD. It is predominantly expressed on Type I IFN-producing cells (IPCs) in naive mice, but is up-regulated on most cell types following stimulation with type I IFNs and IFN-gamma. It is highly expressed on terminally differentiated normal plasmacytoid dendritic cells and some tumor cells, such as multiple myeloma, renal cell carcinoma, and melanoma cells. BST2 is a recently identified, IFN-induced cellular response factor that blocks release of HIV-1 and other retroviruses from infected cells. BST2 has been found to be the natural ligand of ILT7 in human model.
-
Pathways
- Regulation of Leukocyte Mediated Immunity, Production of Molecular Mediator of Immune Response
Target
-